J. Vittitow

发表

A randomized, placebo‐controlled study to evaluate safety and pharmacokinetics of inhaled ribavirin

A. Brkovic, M. Barakat, R. Israel, 2022, Clinical and translational science.

Genes expressed in the human trabecular meshwork during pressure‐induced homeostatic response

T. Borrás, J. Vittitow, 2004, Journal of cellular physiology.

Caldesmon transgene expression disrupts focal adhesions in HTM cells and increases outflow facility in organ-cultured human and monkey anterior segments.

P. Kaufman, B. Geiger, A. Bershadsky, 2006, Experimental eye research.

Comparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension: The LUNAR Study.

F. Medeiros, R. Weinreb, K. Martin, 2016, American journal of ophthalmology.

Loteprednol etabonate (submicron) ophthalmic gel 0.38% dosed three times daily following cataract surgery: integrated analysis of two Phase III clinical studies

M. Cavet, H. DeCory, R. Fong, 2019, Clinical ophthalmology.

Loteprednol etabonate gel 0.5% vs prednisolone acetate suspension 1% for the treatment of inflammation after cataract surgery in children.

Jon I Williams, J. Vittitow, 2018, Journal of cataract and refractive surgery.

Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation.

C. Crean, J. Boyer, E. Akpek, 2009, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

Gene transfer of dominant-negative RhoA increases outflow facility in perfused human anterior segment cultures.

D. Epstein, E. T. O'Brien, T. Borrás, 2002, Molecular vision.

Low‐dose brimonidine for relief of ocular redness: integrated analysis of four clinical trials

G. Torkildsen, E. McLaurin, J. Vittitow, 2018, Clinical & experimental optometry.

Nitric oxide (NO): an emerging target for the treatment of glaucoma.

E. Ongini, M. Cavet, E. Bastia, 2014, Investigative ophthalmology & visual science.

Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings

P. Kaufman, R. Weinreb, J. Liebmann, 2017, Journal of glaucoma.

Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study

R. Weinreb, M. Araie, Y. Kuwayama, 2016, Advances in Therapy.

Evaluation of the Effect of Latanoprostene Bunod Ophthalmic Solution, 0.024% in Lowering Intraocular Pressure over 24 h in Healthy Japanese Subjects

R. Weinreb, M. Araie, B. S. Sforzolini, 2015, Advances in Therapy.

A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study

P. Kaufman, R. Weinreb, Kuldev Singh, 2014, British Journal of Ophthalmology.

Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study.

R. Weinreb, J. Liebmann, J. Vittitow, 2016, Ophthalmology.

Long-term Efficacy and Safety of Latanoprostene Bunod 0.024% for Intraocular Pressure Lowering in Patients with Open-Angle Glaucoma or Ocular Hypertension: APOLLO and LUNAR Studies

P. Kaufman, F. Medeiros, R. Weinreb, 2016 .

Caldesmon effects on the actin cytoskeleton and cell adhesion in cultured HTM cells.

Benjamin Geiger, P. Kaufman, B. Geiger, 2006, Experimental eye research.

Efficacy of Latanoprostene Bunod 0.024% Compared With Timolol 0.5% in Lowering Intraocular Pressure Over 24 Hours.

R. Weinreb, John H. K. Liu, J. Vittitow, 2016, American journal of ophthalmology.

Latrunculin B Reduces Intraocular Pressure in Human Ocular Hypertension and Primary Open-Angle Glaucoma.

R. Ritch, P. Kaufman, C. Rasmussen, 2014, Translational vision science & technology.

Expression of optineurin, a glaucoma-linked gene, is influenced by elevated intraocular pressure.

T. Borrás, J. Vittitow, 2002, Biochemical and biophysical research communications.

In Vitro Inhibition of Evaporation with Perfluorohexyloctane, an Eye Drop for Dry Eye Disease

D. Borchman, H. DeCory, R. Kissling, 2023, Current therapeutic research, clinical and experimental.

Clinical Trials Latrunculin B Reduces Intraocular Pressure in Human Ocular Hypertension and Primary Open-Angle Glaucoma

R. Ritch, P. Kaufman, C. Rasmussen, 2014 .

Oxygen-Carrying Capacity of Perfluorohexyloctane, a Novel Eye Drop for Dry Eye Disease

D. Borchman, N. Stolowich, R. Kissling, 2023, Current therapeutic research, clinical and experimental.

Submicron loteprednol etabonate ophthalmic gel 0.38% for the treatment of inflammation and pain after cataract surgery.

J. Peace, Jon I Williams, B. Silverstein, 2018, Journal of cataract and refractive surgery.

Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study.

R. Weinreb, J. Liebmann, J. Vittitow, 2016, Ophthalmology.

Long-Term Safety and Efficacy of Perfluorohexyloctane Ophthalmic Solution for the Treatment of Patients With Dry Eye Disease: The KALAHARI Study

M. Korenfeld, J. Vittitow, Bruce Segal, 2023, Cornea.

NOV03 for Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction: the Randomized Phase 3 MOJAVE Study: NOV03 for Dry Eye Disease Associated With Meibomian Gland Dysfunction (69 characters; limit, 60).

J. Sheppard, S. Krösser, Alice T. Epitropoulos, 2023, American journal of ophthalmology.

NOV03 for Dry Eye Disease Associated With Meibomian Gland Dysfunction: Results of the Randomized Phase 3 GOBI Study.

S. Krösser, J. Tauber, D. Wirta, 2022, Ophthalmology.

Loteprednol etabonate gel 0.5% vs prednisolone acetate suspension 1% for the treatment of inflammation after cataract surgery in children.

Jon I Williams, J. Vittitow, 2020, Journal of cataract and refractive surgery.